91 related articles for article (PubMed ID: 18648351)
1. VTE and mortality associated with erythropoiesis-stimulating agents in cancer-associated anemia.
Dronca RS; Steensma DP
Nat Clin Pract Oncol; 2008 Sep; 5(9):504-5. PubMed ID: 18648351
[TBL] [Abstract][Full Text] [Related]
2. Tumor progression associated with erythropoiesis-stimulating agents.
Newland AM; Black CD
Ann Pharmacother; 2008 Dec; 42(12):1865-70. PubMed ID: 19017828
[TBL] [Abstract][Full Text] [Related]
3. Is intravenous iron supplementation with erythropoiesis-stimulating agents beneficial in cancer patients with anemia?
Bohlius J
Nat Clin Pract Oncol; 2008 Dec; 5(12):688-9. PubMed ID: 18936789
[TBL] [Abstract][Full Text] [Related]
4. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
Aapro M; Spivak JL
Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
[TBL] [Abstract][Full Text] [Related]
5. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
6. Risk of venous thromboembolism with the erythropoiesis-stimulating agents (ESAs) for the treatment of cancer-associated anemia: a meta-analysis of randomized control trials.
Zhan P; Wang Q; Qian Q; Yu LK
Chin Clin Oncol; 2012 Dec; 1(2):19. PubMed ID: 25841397
[TBL] [Abstract][Full Text] [Related]
7. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients.
Sinclair AM; Todd MD; Forsythe K; Knox SJ; Elliott S; Begley CG
Cancer; 2007 Aug; 110(3):477-88. PubMed ID: 17582631
[TBL] [Abstract][Full Text] [Related]
8. Examining the involvement of erythropoiesis-stimulating agents in tumor proliferation (erythropoietin receptors, receptor binding, signal transduction), angiogenesis, and venous thromboembolic events.
Fandrey J; Dicato M
Oncologist; 2009; 14 Suppl 1():34-42. PubMed ID: 19762515
[TBL] [Abstract][Full Text] [Related]
9. Erythropoiesis stimulating agents, thrombosis and cancer.
Barbera L; Thomas G
Radiother Oncol; 2010 Jun; 95(3):269-76. PubMed ID: 20219259
[TBL] [Abstract][Full Text] [Related]
10. Update on the use of erythropoiesis-stimulating agents (ESAs) for the management of anemia of multiple myeloma and lymphoma.
Katodritou E; Dimopoulos MA; Zervas K; Terpos E
Cancer Treat Rev; 2009 Dec; 35(8):738-43. PubMed ID: 19733008
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
12. Erythropoietin in cancer-related anemia.
Fenner MH; Ganser A
Curr Opin Oncol; 2008 Nov; 20(6):685-9. PubMed ID: 18841051
[TBL] [Abstract][Full Text] [Related]
13. [Erythropoiesis-stimulating agents in chronic kidney disease: which route of administration?].
Borrelli S; Baldanza D; Scigliano R; Catapano F; Grimaldi M; Calabria M; Zamboli P; Minutolo R; De Nicola L; Conte G
G Ital Nefrol; 2009; 26(1):31-7. PubMed ID: 19255962
[TBL] [Abstract][Full Text] [Related]
14. The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?
Singh AK
Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S5-13. PubMed ID: 19010260
[TBL] [Abstract][Full Text] [Related]
15. Is nephrology more at ease than oncology with erythropoiesis-stimulating agents? Treatment guidelines and an update on benefits and risks.
Locatelli F; Gascón P
Oncologist; 2009; 14 Suppl 1():57-62. PubMed ID: 19762517
[TBL] [Abstract][Full Text] [Related]
16. Evolving statistical methods to facilitate evaluation of the causal association between erythropoiesis-stimulating agent dose and mortality in nonexperimental research: strengths and limitations.
Bradbury BD; Brookhart MA; Winkelmayer WC; Critchlow CW; Kilpatrick RD; Joffe MM; Feldman HI; Acquavella JF; Wang O; Rothman KJ
Am J Kidney Dis; 2009 Sep; 54(3):554-60. PubMed ID: 19592144
[TBL] [Abstract][Full Text] [Related]
17. Anemia management in oncology and hematology.
Spivak JL; Gascón P; Ludwig H
Oncologist; 2009; 14 Suppl 1():43-56. PubMed ID: 19762516
[TBL] [Abstract][Full Text] [Related]
18. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
19. Erythropoiesis-stimulating agents in patients with cancer: update on safety issues.
Pirker R
Expert Opin Drug Saf; 2009 Sep; 8(5):515-22. PubMed ID: 19637988
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and initial treatment of venous thromboembolism in patients with cancer.
Streiff MB
J Clin Oncol; 2009 Oct; 27(29):4889-94. PubMed ID: 19738109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
